Patients should be informed when AI systems are used in clinical trials - Nature Medicine

  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 53%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Patients should be informed when artificial intelligence AI systems are used in clinical trials. Correspondence from dbittermanmd and colleagues BrighamWomens DanaFarber

Artificial intelligence systems are increasingly being investigated in clinical trials. Trials that use AI must be held to the same ethical standards for risk assessment and disclosure as all human participant studies.

All clinical AI systems, especially those under active investigation, have new risks, including human–machine interactions, interpretability and data limitations. The full magnitude and scope of these risks is not yet known because clinical AI integration is still in its infancy.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 451. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

AI-generated text may have a role in evidence-based medicine - Nature MedicineAI-generated text, such as from chatGPT, may have a role in evidence-based medicine. Correspondence from pengyifan JFRousseau_MD Edward H. Shortliffe and nychunhua WCMPopHealthSci
Source: NatureMedicine - 🏆 451. / 53 Read more »

The flash dance of midlife: the Skylight 1 trial - Nature MedicineFor women who choose nonhormonal therapy for HotFlashes in menopause, fezolinetant is one of several modestly efficacious and safe options — but women want more. Read the News and Views from Andrea LaCroix and Kristine Ensrud. UMNews UCSanDiego
Source: NatureMedicine - 🏆 451. / 53 Read more »

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial - Nature MedicineA safety and efficacy trial of a single intratumoral dose of the oncolytic adenovirus DNX-2401 followed by intravenous anti-PD-1 pembrolizumab in patients with recurrent glioblastoma shows an encouraging clinical benefit rate and 12 months overall survival.
Source: NatureMedicine - 🏆 451. / 53 Read more »

How AI Will Change Medicine ForeverWith news that AI has helped discover a superbug-killing antibotic, let's take a look at some of the other ways we expect AI will impact medicine. How do YOU think AI will impact our health?
Source: DiscoverMag - 🏆 459. / 53 Read more »